Deutsche Bank Maintains a 'Hold' on Genzyme (GENZ); Genetics Sale-More Upside if Diagnostics Sold
Tweet Send to a Friend
Deutsche Bank maintains a 'Hold' on Genzyme (Nasdaq: GENZ), price target increased from $72 to $76.
Deutsche analyst says, "GENZ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Deutsche analyst says, "GENZ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
